Pulmonary Hypertension

Clinical Trials

Below is a list of Pulmonary Hypertension clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension PAH Disease Management
This study is being done to better understand the medical management of patients with a new or existing diagnosis of PAH. Other objectives include describing the demographic and clinical characteristics of PAH patients as well as identifying medical practices associated with improved health outcomes. This study will collect information on approximately 3,000 patients with PAH at approximately 50 sites in the United States. Data will be collected on patients for at least five years, including past data, if applicable (data from medical records that were recorded prior to the start of the REVEAL Registry) and follow-up telephone and clinic visit data.

As this is an information-gathering study only, your physician will manage your care no differently than he/she would if you were not part of this registry program. You do not need to participate in the REVEAL Registry to receive treatment for your condition. Participating in the REVEAL Registry will not influence the usual care that you receive from your doctor. Specifically, the care you receive from your doctor while participating in the REVEAL Registry will be the same as the care you would receive if you were not participating in this research program.
Read more

SR-PAAS - Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil
This is a clinical research study designed to evaluate the safety and effectiveness of sitaxsentan 100 mg tablet (given by mouth) compared to placebo (a tablet that does not contain any medicine) for the treatment of pulmonary arterial hypertension.
Read more

Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcomes
The main purpose of this clinical research is to find out if this investigational medication (ACT-064992) can delay the time to clinical worsening of your condition. In other words, this investigational medication might improve your health by:

-- Improving the symptoms you experience from your disease
-- Increasing your ability to exercise
-- Improving your pulmonary artery pressure
-- Preventing your disease from worsening
-- Improving your quality of life
Read more